Cipla’s arm receives final approval for generic version of Pfizer’s Lyrica

22 Jul 2019 Evaluate

Cipla’s wholly-owned subsidiary -- InvaGen Pharmaceuticals, Inc. has received final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (USFDA).

InvaGen’s Pregabalin Capsules is AB-rated generic therapeutic equivalent version of Pfizer’s Lyrica. Pregabalin capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, management of fibromyalgia and management of neuropathic pain associated with spinal cord injury.

According to IQVIA (IMS Health), Lyrica had US sales of approximately $5.4 billion for the 12-month period ending March 2019. The product is available for shipping immediately.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1323.95 3.60 (0.27%)
30-Jan-2026 15:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1215.70
Cipla 1323.95
Zydus Lifesciences 888.50
Lupin 2150.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×